Submitted:
03 February 2023
Posted:
03 February 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design, location, population and period
2.2. Study setting
2.3. Data management, ethical considerations
3. Results
3.1. Respondent identification
3.2. Knowledge of the respondents on Covid-19 and vaccination
3.3. Acceptance of the COVID-19 vaccine by the populations
3.4. Determinants of acceptance of vaccination against Covid 19
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Morens, D.M.; Daszak, P.; Taubenberger, J.K. Escaping Pandora’s box—another novel coronavirus. N Engl J Med 2020, 382, 1293–1295. [Google Scholar] [CrossRef] [PubMed]
- Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020, 395, 507–513. [Google Scholar] [CrossRef] [PubMed]
- Victoria, C.L.; Arati, K.; Nelia, M.A. COVID-19 vaccine hesitancy among medical students. J Public Health (Oxf) 2020. [Google Scholar] [CrossRef]
- WHO. Weekly epidemiological update on COVID-19–30 November 2022, Edition 120, 30 November 2022, Emergency Situational Updates. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2022, consulted on 05/12/2022 at 19h30).
- WHO Africa, The future of WHO Covid-19 response operations in Africa in 2022. (https://www.afro.who.int/publications/future-who-covid-19-response-operations-africa-2022, consulted on 05/12/2022 at 20h10).
- OMS. Novel Coronavirus (2019-nCoV) Situation Report-11. Avaible online: www.who.int, (accessed on 31 janvier 2020).
- WHO. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries”. Geneva; 2021. Available online: https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries, (Accessed on 20 January 2023, 19h30).
- Markus, H.; Hannah, K.; Simon, S.; Nadine, K. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
- WHO. COVAX-Working for global equitable access to COVID-19 vaccines. Geneva; 2022. Available online: https://www.who.int/initiatives/act-accelerator/covax, (Accessed on 20 January 2023, 19h).
- Yu, Z.; Zixian, Z.; Yujia, W.; Yueqing, Z. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv 2020. [Google Scholar] [CrossRef]
- Silva-Filho, J.; Caruso-Neves, C.; Pinheiro, A. Angiotensin II type-1 receptor (AT1R) regulates expansion, differentiation, and functional capacity of antigen-specific CD8+ T cells. Sci Rep 2016, 6, 35997. [Google Scholar] [CrossRef] [PubMed]
- Grech, V.; Gauci, C. WITHDRAWN: Vaccine hesitancy in the University of Malta Faculties of Health Sciences, Dentistry and Medicine vis-à-vis influenza and novel COVID-19 vaccination. Early Human Development 2020, 105258. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Wong, E.; Ho, K.; Cheung, A.; Chan, E.; Yeoh, E.; Wong, S. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. Vaccine 2020, 38(45), 7049–7056. [Google Scholar] [CrossRef] [PubMed]
- Cécile, D.; Elodie, N.; Gildas, T. Knowledge, Attitudes and Practices of Populations Towards Barrier and Preventive Measures Against COVID-19 in Two Cities in Cameroon. World J Public Health 2021, 6, 89–98. [Google Scholar] [CrossRef]
- Boum, Y.; Fai, K.; Nikolay, B.; Mboringong, A.; Bebell, L.; Ndifon, M.; et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. The Lancet Infectious Diseases 2021, 21(8), 1089–1096. [Google Scholar] [CrossRef] [PubMed]
- Roman, W.; Victor, M.; Corman, W.; Michael, S. Virological assessment of hospitalized patients with COVID-2019. Nature 2020, 581, 465–469. [Google Scholar] [CrossRef]
- Jeffrey, Lazarus; Katarzyna, Wyka; Trenton, White; Camila, Picchio; Lawrence, Gostin; Heidi, Larson; et al. A Survey of COVID-19 Vaccine Acceptance across 23 Countries in 2022. Nature medicine 2023, 23. [Google Scholar] [CrossRef]
- Mohamed-Amine, C.; Diana C., Sanchez-Ramirez; Margriet, P.; Mohy, U.; Caroline, M.; Shabbir, S-A. COVID-19 Infodemic and Digital Health Literacy in Vulnerable Populations: A Scoping Review. Digital Health 2022, 8, 1–13. [Google Scholar] [CrossRef]
- Barbieri, V.; Wiedermann, C.J.; Lombardo, S.; Plagg, B.; Gärtner, T.; Ausserhofer, D.; Wiedermann, W.; Engl, A.; Piccoliori, G. Rural-Urban Disparities in Vaccine Hesitancy among Adults in South Tyrol, Italy. Vaccines 2022, 10, 1870. [Google Scholar] [CrossRef] [PubMed]
- Simanjorang, C.; Pangandaheng, N.; Tinungki, Y.; Medea, G. The determinants of SARS-CoV-2 vaccine hesitancy in a rural area of an Indonesia–Philippines border island: A mixed-method study. Enfermería Clínica (English Edition) 2022, 32(6), 376–384. [Google Scholar] [CrossRef] [PubMed]
- Sharma, R.; Jelly, P.; AS, V.; Chadha, L.; Saxena, V.; Mohan, L. A Comparative Study of Attitudes towards COVID-19 Vaccination in The Rural and Urban Population of Uttarakhand, India. Journal of Global Health Economics and Policy 2021, 1, e2021018. [Google Scholar] [CrossRef]
- Lazarus, J.; Ratzan, S.; Palayew, A.; Gostin, L.; Larson, H.; Rabin, K.; et al. A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine 2021, 27(2), 225–228. [Google Scholar] [CrossRef] [PubMed]
| Variables | Urban (N=611) |
Rural area (N=442) |
Overall (N=1053) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Age | |||
| [18-30[ | 420 (68.74) | 312 (70.59) | 732 (69.52) |
| [30 - 42[ | 121 (19.80) | 89 (20.14) | 210 (19.94) |
| >42 | 70 (11.46) | 41 (9.28) | 111 (10.54) |
| Marital status | |||
| Single | 373 (61.05) | 277(62.67) | 650 (61.73) |
| Divorced/Widow | 12 (1.96) | 3 (0.68) | 15 (1.42) |
| Married | 226 (36.99) | 162 (36.65) | 388 (36.85) |
| Sex | |||
| Féminin | 519 (84.94) | 374 (84.62) | 893 (84.81) |
| Masculin | 92 (15.06) | 68 (15.38) | 160 (15.19) |
| Profession | |||
| Trader | 119 (19.48) | 87 (19.68) | 206 (19.56) |
| Student | 24 (3.93) | 64 (14.48) | 88 (8.36) |
| Resourceful | 384 (62.85) | 212 (47.96) | 596 (56.60) |
| Others | 841 (3.75) | 79 (17.87) | 163 (15.48) |
| Level of education | |||
| None | 64 (10.47) | 157 (35.52) | 221 (20.99) |
| Primary | 271 (44.35) | 165 (37.33) | 436 (41.41) |
| Secondary | 99 (16.20) | 36 (8.14) | 135 (12.82) |
| Superior | 177 (28.97) | 84 (19.00) | 261 (24.79) |
| Religion | |||
| Animist | 2 (0.33) | 2 (0.45) | 4 (0.38) |
| Christian | 574 (93.94) | 413 (93.44) | 987 (93.73) |
| Muslim | 35 (5.73) | 27 (6.11) | 62 (5.89) |
| Variables | Urban (N=611) |
Rural (N=442) |
P-value | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| COVID-19 exists | ||||
| No | 15 (2.45) | 66 (14.93) | ||
| Yes | 596 (97.55) | 376 (85.07) | <0.0001 | |
| Modes of transmission | ||||
| No | 420 (68.74) | 292 (66.06) | ||
| Yes | 191 (31.26) | 150 (33.94) | 0.3602 | |
| The symptoms of Covid 19 are: | ||||
| No | 581 (95.09) | 336 (76.02) | ||
| Yes | 30 (4.91) | 106 (23.98) | <0.0001 | |
| We can recover from COVID-19 without treatment | ||||
| No | 377 (61.70) | 318 (71.95) | ||
| Yes | 234 (38.30) | 124 (28.05) | 0.0005 | |
| We can be infected several times by COVID19 | ||||
| No | 109 (17.84) | 280 (63.35) | ||
| Yes | 502 (82.16) | 162 (36.65) | <0.0001 | |
| There is a vaccine against COVID-19 | ||||
| No | 17 (2.78) | 77 (17.42) | ||
| Yes | 594 (97.22) | 365 (82.58) | <0.0001 | |
| Anti Covid Vaccination can be effective | ||||
| No | 195 (31.91) | 183 (41.40) | ||
| Yes | 416 (68.09) | 259 (58.60) | 0.0016 | |
| Variables | Urban (N=611) | Rural (N=442) | P-value | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Would you agree to receive COVID-19 vaccine? | ||||
| Neutral | 274 (44.84) | 228 (51.58) | Ref | |
| Agree | 260 (42.55) | 147 (33.26) | 0.0047 | |
| Disagree | 77 (12.60) | 67 (15.16) | 0.8137 | |
| Reasons for not accepting the Covid-19 vaccine | ||||
| It is a negligible threat disease and can be cured | 48 (7.86) | 27 (6.11) | Ref | |
| I don’t have enough information about the vaccine | 186 (30.44) | 102 (23.08) | 0.9251 | |
| It is to give us a disease | 54 (8.84) | 155 (35.07) | <0.0001 | |
| The vaccine may be not safe due to the speed of synthesis | 323 (52.86) | 158 (35.75) | 0.5902 | |
| Variables | Vaccine acceptance (Urban area) |
Vaccine acceptance (Rural area) |
||
|---|---|---|---|---|
| %(n/N) | P-value, OR (95% CI) | %(n/N) | P-value, OR (95% CI) | |
| Age | ||||
| [18-30[ | 40.00(168/420) | Ref | 34.94(109/312) | Ref |
| [30–42[ | 47.11(57/121) | 0.16291, 0.34 (0.89-2.01) | 31.46(28/89) | 0.5422, 0.85 (0.52-1.42) |
| > 42 | 50.00(35/70) | 0.11741, 0.50 (0.90-2.49) | 24.39(10/41) | 0.1829, 0.60 (0.28-1.27) |
| Marital status | ||||
| Single | 39.41(147/373) | Ref | 31.77(88/277) | Ref |
| Married | 44.69(101/226) | 0.2038 1,24 (0.89-1.74) | 36.42(59/162) | 0.3194, 1.23 (0.82-1.85) |
| Sex | ||||
| Féminin | 41.81(217/519) | Ref | 33.69(126/374) | Ref |
| Masculin | 46.74(43/92) | 0.3788, 1.22 (0.78-1.91) | 30.88(21/68) | 0.6514, 0.88 (0.50-1.54) |
| Profession | ||||
| Resourceful | 47.66(183/384) | Ref | 38.68(82/212) | Ref |
| Trader | 32.77(39/119) | 0.0046, 0.54 (0.35-0.82) | 11.49(10/87) | <0.0001, 0.21 (0.10-0.42) |
| Student | 41.67(10/24) | 0.5694, 0.78 (0.34-1.81) | 45.31(29/64) | 0.34361,31,752,31 |
| Others | 33.33(28/84) | 0.0578, 0.55 (0.33-0.90) | 32.91(26/79) | 0.3657, 0.78 (0.45-1.34) |
| Level of education | ||||
| None | 43.75(28/64) | Ref | 23.57(37/157) | Ref |
| Primary | 35.06(95/271) | 0.1957, 0.69 (0.40-1.21) | 42.24(73/165) | 0.1522, 1.54 (0.85-2.77) |
| Secondary | 46.46(46/99) | 0.73391, 0.12 (0.59-2.10) | 27.78(10/36) | 0.5960, 1.25 (0.55-2.82) |
| Superior | 51.41(91/177) | 0.2942, 1.36 (0.77-2.42) | 32.14(27/84) | 0.0001, 2.57 (1.59-4.16) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).